Skip to main content
Clinical Trials/NCT01879956
NCT01879956
Unknown
Not Applicable

Randomized Controlled Trial for the Evaluation of the Efficacy of Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Refractory Schizophrenia

University of Sao Paulo1 site in 1 country60 target enrollmentFebruary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Refractory Schizophrenia
Sponsor
University of Sao Paulo
Enrollment
60
Locations
1
Primary Endpoint
BADS (Behavioral Assessment of Functional Status)
Last Updated
12 years ago

Overview

Brief Summary

Primary Objective:

Efficacy of Occupational Therapy (OT) based Occupational Goal Intervention (OGI) in improving executive functions in patients with refractory schizophrenia as measured by the BADS.

Secondary Objectives: improvement of functional aspects,basic and instrumental activities of daily living,negative symptoms and cognitive functions improvement

Hypothesis: OT is more effective than control group to improve executive functions in patients with refractory schizophrenia.

Detailed Description

A single-center, randomized, single blind, controlled study, lasting one year, including the follow-up. The study is conducted in two groups:the experimental group is based on the OGI method (N=30 patients) and the control group receives craft activities (N = 30 patients). Psychiatric, neuropsychological and functional aspects are assessed at the beginning, after 30 sessions and 6 months after the intervention. The scale PANSS (Positive and Negative Syndrome Scale) is used for monitoring psychopathological symptoms during the study. Scales BADS, DAFS-R, ILSS-BR respectively assess executive functions, functionality and basic and instrumental activities of daily living. The neuropsychological evaluation includes a battery to measure attention, executive functions, memory and estimated intellectual efficiency. Statistical analysis to be used: ANOVA (Analysis of Variance)for repeated measures; data are also calculated to messure clinical efficacy, effect size and needed number to treat.

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
September 2014
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Helio Elkis

Associate Professor of the Department of Psychiatry

University of Sao Paulo

Eligibility Criteria

Inclusion Criteria

  • Pacients with diagnosis of schizophrenia for DMS IV-R.
  • Pacients that signed the consent in writing and receive explanations about the nature of the study.
  • Patients who carefully counted another responsible person to provide reliable support to the patient and ensure adherence to the same study treatment.
  • Patients with minimum education: five years (elementary school).
  • Patients who present rates below those expected for their age group in at least 3 of the executive functions assessed on neuropsychological tests, and evaluation of executive functions.
  • Patients with stable clozapine and which have not been recently admitted (3 months).

Exclusion Criteria

  • Comorbid diagnosis of substance dependence or other psychiatric Axis I;
  • History of head trauma and / or other neurological problems;
  • Medical problems that compromise somehow the central nervous system;
  • History of mental retardation;
  • Patients treated with medication other than clozapine;
  • Patients who are suffering other psychosocial treatments.

Outcomes

Primary Outcomes

BADS (Behavioral Assessment of Functional Status)

Time Frame: up to 6 months follow-up.

It is a battery which measures neuropsychological executive functions.

Secondary Outcomes

  • DAFS-BR ( Direct Assessment of Functional Status), ILSS-BR (Habilities of Daily Living-Brazilian validated version).(at baseline, after 30 sessions of treatment and follow-up 6 months.)
  • Trail Making A/B, Digit Span, Wisconsin Card Sorting Test, Stroop Color Test, Rey Complex Figure, Verbal Fluency,Tapping Visual and Logical Memory.(at baseline, after 30 sessions of treatment and 6 months follo-up.)

Study Sites (1)

Loading locations...

Similar Trials